A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
Inclusion Criteria:
- Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
OYS, Finland
Ambroise, France
Ferolles-Attily, France
Vandoeuvre Les Nancys, France
Huxquilucan, Mexico
Muenchenstein, Switzerland
Büyükçekmece / Ýstanbul, Turkey (Türkiye)
Fatih / Istanbul, Turkey (Türkiye)
Mecidiyekoy/Istanbul, Turkey (Türkiye)
Soke / Aydin, Turkey (Türkiye)
Yenisehir/Izmir, Turkey (Türkiye)